David Carter is a member of CRG’s Founders Group and serves as Partner and member of CRG’s Investment Committee. Mr. Carter joined CRG in 2003 and has more than 25 years of investment and advisory experience. Mr. Carter leads the due diligence efforts related to CRG’s investments in the medical device, specialty pharma, drug delivery, biopharma and tools & diagnostic sectors. Mr. Carter, in addition to focusing on sourcing, execution and monitoring existing CRG investments is responsible for staffing CRG deal teams. Prior to joining CRG, Mr. Carter was a partner at Palestra Capital, a hedge fund focused on risk arbitrage and special situations. Before joining Palestra, Mr. Carter was a high yield analyst at Furman Selz LLC, where he was responsible for coverage of healthcare-related high yield debt. Previously, Mr. Carter was an investment banking analyst in the Healthcare Group at Chemical Bank and a research assistant in the Mergers & Acquisitions Group of Morgan Stanley. Over the course of his career, Mr. Carter has closed in excess of $5 billion of financing activity.
Mr. Carter received a Bachelor of Science in finance from The Pennsylvania State University in 1988. He received a Master of Arts degree in information science and systems in 1994 and an M.B.A. in 1996, both from Columbia University.